vs
科慕（CC）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
科慕的季度营收约是Revvity的1.7倍（$1.3B vs $772.1M），Revvity净利率更高（12.7% vs -3.5%，领先16.3%），Revvity同比增速更快（5.9% vs -2.1%），Revvity自由现金流更多（$161.8M vs $92.0M），过去两年Revvity的营收复合增速更高（9.0% vs -1.2%）
科慕公司是一家美国化工企业，2015年7月从杜邦分拆成立，总部位于美国特拉华州威尔明顿。公司主营产品包括具备不粘特性的知名品牌特氟龙（聚四氟乙烯PTFE）、二氧化钛以及制冷剂气体，在特种化工领域拥有深厚的技术积累。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
CC vs RVTY — 直观对比
营收规模更大
CC
是对方的1.7倍
$772.1M
营收增速更快
RVTY
高出7.9%
-2.1%
净利率更高
RVTY
高出16.3%
-3.5%
自由现金流更多
RVTY
多$69.8M
$92.0M
两年增速更快
RVTY
近两年复合增速
-1.2%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $1.3B | $772.1M |
| 净利润 | $-47.0M | $98.4M |
| 毛利率 | 11.7% | — |
| 营业利润率 | — | 14.5% |
| 净利率 | -3.5% | 12.7% |
| 营收同比 | -2.1% | 5.9% |
| 净利润同比 | -261.5% | 3.9% |
| 每股收益（稀释后） | $-0.32 | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CCRVTY
| Q4 25 | $1.3B | $772.1M | ||
| Q3 25 | $1.5B | $698.9M | ||
| Q2 25 | $1.6B | $720.3M | ||
| Q1 25 | $1.4B | $664.8M | ||
| Q4 24 | $1.4B | $729.4M | ||
| Q3 24 | $1.5B | $684.0M | ||
| Q2 24 | $1.6B | $691.7M | ||
| Q1 24 | $1.4B | $649.9M |
净利润CCRVTY
| Q4 25 | $-47.0M | $98.4M | ||
| Q3 25 | $46.0M | $46.7M | ||
| Q2 25 | $-380.0M | $53.9M | ||
| Q1 25 | $-5.0M | $42.2M | ||
| Q4 24 | $-13.0M | $94.6M | ||
| Q3 24 | $-32.0M | $94.4M | ||
| Q2 24 | $60.0M | $55.4M | ||
| Q1 24 | $54.0M | $26.0M |
毛利率CCRVTY
| Q4 25 | 11.7% | — | ||
| Q3 25 | 15.6% | 53.6% | ||
| Q2 25 | 17.2% | 54.5% | ||
| Q1 25 | 17.3% | 56.5% | ||
| Q4 24 | 19.4% | — | ||
| Q3 24 | 19.0% | 56.3% | ||
| Q2 24 | 19.8% | 55.7% | ||
| Q1 24 | 20.9% | 54.6% |
营业利润率CCRVTY
| Q4 25 | — | 14.5% | ||
| Q3 25 | 2.5% | 11.7% | ||
| Q2 25 | -15.4% | 12.6% | ||
| Q1 25 | — | 10.9% | ||
| Q4 24 | -0.1% | 16.3% | ||
| Q3 24 | -2.1% | 14.3% | ||
| Q2 24 | 4.4% | 12.4% | ||
| Q1 24 | 5.1% | 6.8% |
净利率CCRVTY
| Q4 25 | -3.5% | 12.7% | ||
| Q3 25 | 3.1% | 6.7% | ||
| Q2 25 | -23.5% | 7.5% | ||
| Q1 25 | -0.4% | 6.4% | ||
| Q4 24 | -1.0% | 13.0% | ||
| Q3 24 | -2.1% | 13.8% | ||
| Q2 24 | 3.9% | 8.0% | ||
| Q1 24 | 4.0% | 4.0% |
每股收益（稀释后）CCRVTY
| Q4 25 | $-0.32 | $0.86 | ||
| Q3 25 | $0.31 | $0.40 | ||
| Q2 25 | $-2.53 | $0.46 | ||
| Q1 25 | $-0.03 | $0.35 | ||
| Q4 24 | $-0.07 | $0.77 | ||
| Q3 24 | $-0.22 | $0.77 | ||
| Q2 24 | $0.39 | $0.45 | ||
| Q1 24 | $0.36 | $0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $670.0M | $919.9M |
| 总债务越低越好 | $4.1B | — |
| 股东权益账面价值 | $250.0M | $7.3B |
| 总资产 | $7.4B | $12.2B |
| 负债/权益比越低杠杆越低 | 16.40× | — |
8季度趋势，按日历期对齐
现金及短期投资CCRVTY
| Q4 25 | $670.0M | $919.9M | ||
| Q3 25 | $613.0M | $931.4M | ||
| Q2 25 | $502.0M | $991.8M | ||
| Q1 25 | $464.0M | $1.1B | ||
| Q4 24 | $713.0M | $1.2B | ||
| Q3 24 | $596.0M | $1.2B | ||
| Q2 24 | $604.0M | $2.0B | ||
| Q1 24 | $746.0M | $1.7B |
总债务CCRVTY
| Q4 25 | $4.1B | — | ||
| Q3 25 | $4.1B | — | ||
| Q2 25 | $4.1B | — | ||
| Q1 25 | $4.1B | — | ||
| Q4 24 | $4.1B | — | ||
| Q3 24 | $4.0B | — | ||
| Q2 24 | $4.0B | — | ||
| Q1 24 | $4.0B | — |
股东权益CCRVTY
| Q4 25 | $250.0M | $7.3B | ||
| Q3 25 | $274.0M | $7.4B | ||
| Q2 25 | $228.0M | $7.6B | ||
| Q1 25 | $566.0M | $7.6B | ||
| Q4 24 | $571.0M | $7.7B | ||
| Q3 24 | $643.0M | $7.9B | ||
| Q2 24 | $714.0M | $7.9B | ||
| Q1 24 | $753.0M | $7.8B |
总资产CCRVTY
| Q4 25 | $7.4B | $12.2B | ||
| Q3 25 | $7.5B | $12.1B | ||
| Q2 25 | $7.5B | $12.4B | ||
| Q1 25 | $7.4B | $12.4B | ||
| Q4 24 | $7.5B | $12.4B | ||
| Q3 24 | $7.5B | $12.8B | ||
| Q2 24 | $7.2B | $13.4B | ||
| Q1 24 | $8.0B | $13.4B |
负债/权益比CCRVTY
| Q4 25 | 16.40× | — | ||
| Q3 25 | 14.96× | — | ||
| Q2 25 | 17.99× | — | ||
| Q1 25 | 7.18× | — | ||
| Q4 24 | 7.11× | — | ||
| Q3 24 | 6.20× | — | ||
| Q2 24 | 5.53× | — | ||
| Q1 24 | 5.27× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $137.0M | $182.0M |
| 自由现金流经营现金流 - 资本支出 | $92.0M | $161.8M |
| 自由现金流率自由现金流/营收 | 6.9% | 21.0% |
| 资本支出强度资本支出/营收 | 3.4% | 2.6% |
| 现金转化率经营现金流/净利润 | — | 1.85× |
| 过去12个月自由现金流最近4个季度 | $51.0M | $509.4M |
8季度趋势，按日历期对齐
经营现金流CCRVTY
| Q4 25 | $137.0M | $182.0M | ||
| Q3 25 | $146.0M | $138.5M | ||
| Q2 25 | $93.0M | $134.3M | ||
| Q1 25 | $-112.0M | $128.2M | ||
| Q4 24 | $138.0M | $174.2M | ||
| Q3 24 | $139.0M | $147.9M | ||
| Q2 24 | $-620.0M | $158.6M | ||
| Q1 24 | $-290.0M | $147.6M |
自由现金流CCRVTY
| Q4 25 | $92.0M | $161.8M | ||
| Q3 25 | $105.0M | $120.0M | ||
| Q2 25 | $50.0M | $115.5M | ||
| Q1 25 | $-196.0M | $112.2M | ||
| Q4 24 | $29.0M | $149.8M | ||
| Q3 24 | $63.0M | $125.6M | ||
| Q2 24 | $-693.0M | $136.6M | ||
| Q1 24 | $-392.0M | $129.7M |
自由现金流率CCRVTY
| Q4 25 | 6.9% | 21.0% | ||
| Q3 25 | 7.0% | 17.2% | ||
| Q2 25 | 3.1% | 16.0% | ||
| Q1 25 | -14.3% | 16.9% | ||
| Q4 24 | 2.1% | 20.5% | ||
| Q3 24 | 4.2% | 18.4% | ||
| Q2 24 | -44.6% | 19.7% | ||
| Q1 24 | -28.8% | 20.0% |
资本支出强度CCRVTY
| Q4 25 | 3.4% | 2.6% | ||
| Q3 25 | 2.7% | 2.6% | ||
| Q2 25 | 2.7% | 2.6% | ||
| Q1 25 | 6.1% | 2.4% | ||
| Q4 24 | 8.0% | 3.4% | ||
| Q3 24 | 5.0% | 3.3% | ||
| Q2 24 | 4.7% | 3.2% | ||
| Q1 24 | 7.5% | 2.7% |
现金转化率CCRVTY
| Q4 25 | — | 1.85× | ||
| Q3 25 | 3.17× | 2.97× | ||
| Q2 25 | — | 2.49× | ||
| Q1 25 | — | 3.03× | ||
| Q4 24 | — | 1.84× | ||
| Q3 24 | — | 1.57× | ||
| Q2 24 | -10.33× | 2.87× | ||
| Q1 24 | -5.37× | 5.67× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CC
| Titanium Technologies | $563.0M | 42% |
| Thermal And Specialized Solutions | $443.0M | 33% |
| Advanced Performance Materials | $312.0M | 23% |
| Other Non-Reportable Segment | $12.0M | 1% |
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
